Liquid Dosage
Protein-based therapeutics are increasingly being developed as new chemical entities in the pharmaceutical and life science industries. Unlike small molecules, which are typically synthesized using chemical processes, most proteins need to be processed in living systems, mostly by recombinant DNA technology. The proteins can then be produced in their functional form (quaternary structure), rather than by microbial biosynthesis (bacteria/yeast), substantially reducing the downstream stages of the process.
As the demand for large-volume products increases, so does the requirement for higher capacity reactors (up to 20,000 L) to realize economies of scale. GEA has responded to the changing needs of biopharmaceutical manufacturers and developed improved technology solutions to optimize both upstream and, with increasing titers, downstream processing, in terms of time and cost efficiency.
Based on its history of innovation and process development, GEA has a thorough working knowledge of therapeutic protein production and has used this competence to design better media and feeding strategies, optimize the fermentation stage and enhance physicochemical conditions during the manufacturing process.
A leading international supplier of integrated process systems, our extensive portfolio of products, technologies and services includes standard and customized fermenters, separators and entire production lines, as well as plant for the production, storage and distribution of clean utilities. Systems for the preparation of media, fluid management, cell cultivation and purification are also part of our global scope of supply.
As a competent manufacturer of complete plant for the life science industries, GEA is a full-service provider of solutions that meet your exact requirements and specifications. From planning, development and installation to qualification and maintenance, our experienced engineers will collaborate with your project team to supply innovative and efficient process solutions for your applications.
12 の 4 を表示する
GEA の革新的な CIP コンセプトは、包括的な最高規格を満たしています。当社のエキスパートは、プロセスのあらゆる時点で、製品の安全性を保証しています。どのアップグレードも、現場の個々の条件および顧客の要件に適合し、顕著な節約を実現します。
GEA Hilgeでは、飲料、食品、製薬産業における多岐にわたる感度の高い用途に汎用性の高い遠心ポンプおよび容積型ポンプをご用意しております。
GEA's thorough understanding of the lyophilization process enables them to supply a comprehensive range of products and services, comprising laboratory equipment, pilot plants for research and small-scale production batches, industrial size pharmaceutical production freeze dryers.
かねてから、GEA は医薬品およびバイオテクノロジー用途の超高圧 (VHP) ホモジナイザユニットの基準を確立してきました。当社の供給範囲は、細胞の溶解および粒子径の小型化の用途のためのベンチトップの研究室用機器からパイロット規模および生産用のスキッド搭載システムの社内設計・製造に及びます。
The world's population is growing and with it demand for milk. Dairy is an essential component of many global diets. However, its production can be resource-intensive and impact the environment. GEA’s Christian Müller, Senior Director Sustainability Farm Technologies, sheds light on how technological innovations powered by GEA make milk production more efficient and profitable.